Journal
HAEMATOLOGICA
Volume 93, Issue 2, Pages 295-298Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11627
Keywords
amyloidosis; bortezomib; chemotherapy
Categories
Funding
- NHS Research and Development Funds
- Leukaemia Research Fund
- MRC [G7900510] Funding Source: UKRI
Ask authors/readers for more resources
We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Patients received a median of 3 (range 1-6) cycles of bortezomib and 9 (45%) patients received concurrent dexamethasone. Three (15%) patients achieved complete hematologic responses, and a further 13 (65%) achieved partial responses. Fifteen (75%) patients experienced some degree of toxicity, which in 8 (40%) cases resulted in discontinuation of bortezomib. Bortezomib shows promise in the treatment of systemic AL amyloidosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available